Publication | Open Access

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

UrologyOncologyDocetaxel ChemotherapyClinical TrialsImmune Checkpoint InhibitorPharmacotherapyCancer TreatmentProstatic DiseaseMedicineRadiation OncologyIpilimumab Versus PlaceboHealth Sciences